96 related articles for article (PubMed ID: 8877032)
1. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.
Rowland K; Ellis SW; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1996 Sep; 42(3):390-3. PubMed ID: 8877032
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
3. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
4. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
Marathe PH; Shen DD; Nelson WL
Drug Metab Dispos; 1994; 22(2):237-47. PubMed ID: 8013280
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines.
Madani S; Paine MF; Lewis L; Thummel KE; Shen DD
Pharm Res; 1999 Aug; 16(8):1199-205. PubMed ID: 10468020
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
9. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Komura H; Iwaki M
Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
[TBL] [Abstract][Full Text] [Related]
12. Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.
Otton SV; Gillam EM; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1990 Nov; 30(5):751-60. PubMed ID: 2271375
[TBL] [Abstract][Full Text] [Related]
13. Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes.
Narimatsu S; Kobayashi N; Masubuchi Y; Horie T; Kakegawa T; Kobayashi H; Hardwick JP; Gonzalez FJ; Shimada N; Ohmori S; Kitada M; Asaoka K; Kataoka H; Yamamoto S; Satoh T
Chem Biol Interact; 2000 Jun; 127(1):73-90. PubMed ID: 10903420
[TBL] [Abstract][Full Text] [Related]
14. Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions.
Bichara N; Ching MS; Blake CL; Ghabrial H; Smallwood RA
Drug Metab Dispos; 1996 Jan; 24(1):112-8. PubMed ID: 8825198
[TBL] [Abstract][Full Text] [Related]
15. Fenproporex N-dealkylation to amphetamine--enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats.
Kraemer T; Pflugmann T; Bossmann M; Kneller NM; Peters FT; Paul LD; Springer D; Staack RF; Maurer HH
Biochem Pharmacol; 2004 Sep; 68(5):947-57. PubMed ID: 15294457
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 is primarily responsible for the metabolism of clomiphene.
Ghobadi C; Gregory A; Crewe HK; Rostami-Hodjegan A; Lennard MS
Drug Metab Pharmacokinet; 2008; 23(2):101-5. PubMed ID: 18445989
[TBL] [Abstract][Full Text] [Related]
18. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
19. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
